Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
Summary
PITTSBURGH, April 30, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD).Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials, says Paul Radspinner, President & Chief Executive Officer of FluGen. Utilizing our exceptional technology and supported by our team of leading scientists, this work will allow FluGen to continue its clinical trials with greater potential to bring a more advanced and stable flu vaccine to patients.About Predictive OncologyPredictive Oncology (NASDAQ: POAI) is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The companys scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. In an unprecedented challenge trial, M2SR demonstrated protection against infection and illness across seven years of virus drift; and M2SR induces a durable antibody response with potential to cover an entire flu season and beyond. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make.